Cargando…

Cortical atrophy and amyloid and tau deposition in Down syndrome: A longitudinal study

Introduction: The Down syndrome population has a high prevalence for dementia, often showing their first clinical symptoms in their 40s. Methods: In a longitudinal cohort, we investigate whether amyloid deposition at time point 1 (TP1) could predict cortical thickness change at time point 2 (TP2). T...

Descripción completa

Detalles Bibliográficos
Autores principales: Padilla, Concepcion, Montal, Victor, Walpert, Madeleine J., Hong, Young T., Fryer, Tim D., Coles, Jonathan P., Aigbirhio, Franklin I., Hartley, Sigan L., Cohen, Ann D., Tudorascu, Dana L, Christian, Bradley T., Handen, Benjamin L., Klunk, William E., Holland, Anthony J., Zaman, Shahid H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8974205/
https://www.ncbi.nlm.nih.gov/pubmed/35386472
http://dx.doi.org/10.1002/dad2.12288
_version_ 1784680215204593664
author Padilla, Concepcion
Montal, Victor
Walpert, Madeleine J.
Hong, Young T.
Fryer, Tim D.
Coles, Jonathan P.
Aigbirhio, Franklin I.
Hartley, Sigan L.
Cohen, Ann D.
Tudorascu, Dana L
Christian, Bradley T.
Handen, Benjamin L.
Klunk, William E.
Holland, Anthony J.
Zaman, Shahid H.
author_facet Padilla, Concepcion
Montal, Victor
Walpert, Madeleine J.
Hong, Young T.
Fryer, Tim D.
Coles, Jonathan P.
Aigbirhio, Franklin I.
Hartley, Sigan L.
Cohen, Ann D.
Tudorascu, Dana L
Christian, Bradley T.
Handen, Benjamin L.
Klunk, William E.
Holland, Anthony J.
Zaman, Shahid H.
author_sort Padilla, Concepcion
collection PubMed
description Introduction: The Down syndrome population has a high prevalence for dementia, often showing their first clinical symptoms in their 40s. Methods: In a longitudinal cohort, we investigate whether amyloid deposition at time point 1 (TP1) could predict cortical thickness change at time point 2 (TP2). The association between tau burden and cortical thickness was also examined at time point 3 (TP3). Results: Between TP1 and TP2 there was pronounced cortical thinning in temporo‐parietal cortices and cortical thickening in the frontal cortex. Baseline amyloid burden was strongly associated to cortical thinning progression, especially in the temporo‐parietal regions. At TP3, tau deposition negatively correlated with cortical atrophy in regions where tau usually accumulates at later Braak stages. Discussion: A higher amount of amyloid accumulation triggers a cascade of changes of disease‐causing processes that eventually lead to dementia. As expected, we found that regions where tau usually accumulates were those also displaying high levels of cortical atrophy.
format Online
Article
Text
id pubmed-8974205
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-89742052022-04-05 Cortical atrophy and amyloid and tau deposition in Down syndrome: A longitudinal study Padilla, Concepcion Montal, Victor Walpert, Madeleine J. Hong, Young T. Fryer, Tim D. Coles, Jonathan P. Aigbirhio, Franklin I. Hartley, Sigan L. Cohen, Ann D. Tudorascu, Dana L Christian, Bradley T. Handen, Benjamin L. Klunk, William E. Holland, Anthony J. Zaman, Shahid H. Alzheimers Dement (Amst) Neuroimaging Introduction: The Down syndrome population has a high prevalence for dementia, often showing their first clinical symptoms in their 40s. Methods: In a longitudinal cohort, we investigate whether amyloid deposition at time point 1 (TP1) could predict cortical thickness change at time point 2 (TP2). The association between tau burden and cortical thickness was also examined at time point 3 (TP3). Results: Between TP1 and TP2 there was pronounced cortical thinning in temporo‐parietal cortices and cortical thickening in the frontal cortex. Baseline amyloid burden was strongly associated to cortical thinning progression, especially in the temporo‐parietal regions. At TP3, tau deposition negatively correlated with cortical atrophy in regions where tau usually accumulates at later Braak stages. Discussion: A higher amount of amyloid accumulation triggers a cascade of changes of disease‐causing processes that eventually lead to dementia. As expected, we found that regions where tau usually accumulates were those also displaying high levels of cortical atrophy. John Wiley and Sons Inc. 2022-04-01 /pmc/articles/PMC8974205/ /pubmed/35386472 http://dx.doi.org/10.1002/dad2.12288 Text en © 2022 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Neuroimaging
Padilla, Concepcion
Montal, Victor
Walpert, Madeleine J.
Hong, Young T.
Fryer, Tim D.
Coles, Jonathan P.
Aigbirhio, Franklin I.
Hartley, Sigan L.
Cohen, Ann D.
Tudorascu, Dana L
Christian, Bradley T.
Handen, Benjamin L.
Klunk, William E.
Holland, Anthony J.
Zaman, Shahid H.
Cortical atrophy and amyloid and tau deposition in Down syndrome: A longitudinal study
title Cortical atrophy and amyloid and tau deposition in Down syndrome: A longitudinal study
title_full Cortical atrophy and amyloid and tau deposition in Down syndrome: A longitudinal study
title_fullStr Cortical atrophy and amyloid and tau deposition in Down syndrome: A longitudinal study
title_full_unstemmed Cortical atrophy and amyloid and tau deposition in Down syndrome: A longitudinal study
title_short Cortical atrophy and amyloid and tau deposition in Down syndrome: A longitudinal study
title_sort cortical atrophy and amyloid and tau deposition in down syndrome: a longitudinal study
topic Neuroimaging
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8974205/
https://www.ncbi.nlm.nih.gov/pubmed/35386472
http://dx.doi.org/10.1002/dad2.12288
work_keys_str_mv AT padillaconcepcion corticalatrophyandamyloidandtaudepositionindownsyndromealongitudinalstudy
AT montalvictor corticalatrophyandamyloidandtaudepositionindownsyndromealongitudinalstudy
AT walpertmadeleinej corticalatrophyandamyloidandtaudepositionindownsyndromealongitudinalstudy
AT hongyoungt corticalatrophyandamyloidandtaudepositionindownsyndromealongitudinalstudy
AT fryertimd corticalatrophyandamyloidandtaudepositionindownsyndromealongitudinalstudy
AT colesjonathanp corticalatrophyandamyloidandtaudepositionindownsyndromealongitudinalstudy
AT aigbirhiofranklini corticalatrophyandamyloidandtaudepositionindownsyndromealongitudinalstudy
AT hartleysiganl corticalatrophyandamyloidandtaudepositionindownsyndromealongitudinalstudy
AT cohenannd corticalatrophyandamyloidandtaudepositionindownsyndromealongitudinalstudy
AT tudorascudanal corticalatrophyandamyloidandtaudepositionindownsyndromealongitudinalstudy
AT christianbradleyt corticalatrophyandamyloidandtaudepositionindownsyndromealongitudinalstudy
AT handenbenjaminl corticalatrophyandamyloidandtaudepositionindownsyndromealongitudinalstudy
AT klunkwilliame corticalatrophyandamyloidandtaudepositionindownsyndromealongitudinalstudy
AT hollandanthonyj corticalatrophyandamyloidandtaudepositionindownsyndromealongitudinalstudy
AT zamanshahidh corticalatrophyandamyloidandtaudepositionindownsyndromealongitudinalstudy